ENGEX - AAV Trademark

Trademark Overview

On Friday, July 17, 2020, a trademark application was filed for ENGEX - AAV with the United States Patent and Trademark Office. The USPTO has given the ENGEX - AAV trademark a serial number of 90058109. The federal status of this trademark filing is ABANDONED - NO STATEMENT OF USE FILED as of Monday, November 27, 2023. This trademark is owned by Codiak BioSciences, Inc.. The ENGEX - AAV trademark is filed in the Pharmaceutical Products and Computer & Software Services & Scientific Services categories with the following description:

Biological preparations comprising extracellular vesicles known as exosomes for therapeutic applications in the areas of oncology, immune-based diseases, metabolic and fibrotic disorders, neurological disorders, vaccination, and rare diseases

Biopharmaceutical research and development services; pharmaceutical research and development services
engex - aav

General Information

Serial Number90058109
Word MarkENGEX - AAV
Filing DateFriday, July 17, 2020
Status606 - ABANDONED - NO STATEMENT OF USE FILED
Status DateMonday, November 27, 2023
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, March 2, 2021

Trademark Statements

Goods and ServicesBiological preparations comprising extracellular vesicles known as exosomes for therapeutic applications in the areas of oncology, immune-based diseases, metabolic and fibrotic disorders, neurological disorders, vaccination, and rare diseases
Disclaimer with Predetermined Text"AAV"
Goods and ServicesBiopharmaceutical research and development services; pharmaceutical research and development services

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateFriday, August 14, 2020
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE
International Class042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software.
US Class Codes100, 101
Class Status Code6 - Active
Class Status DateFriday, August 14, 2020
Primary Code042
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NameLONZA SALES AG
Party Type21 - New Owner After Publication
Legal Entity Type11 - Company
AddressBASEL CH-4052
CH
Party NameCodiak BioSciences, Inc.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressCambridge, MA 02140
Party NameCodiak BioSciences, Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressCambridge, MA 02140

Trademark Events

Event DateEvent Description
Monday, November 27, 2023ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
Monday, November 27, 2023ABANDONMENT - NO USE STATEMENT FILED
Friday, July 14, 2023TEAS CHANGE OF CORRESPONDENCE RECEIVED
Friday, July 14, 2023ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Friday, July 14, 2023TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Friday, July 14, 2023APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Friday, July 14, 2023TEAS CHANGE OF OWNER ADDRESS RECEIVED
Wednesday, July 12, 2023AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP
Saturday, April 15, 2023NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Thursday, April 13, 2023SOU EXTENSION 4 GRANTED
Thursday, April 13, 2023SOU EXTENSION 4 FILED
Thursday, April 13, 2023SOU TEAS EXTENSION RECEIVED
Saturday, November 5, 2022NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Friday, November 4, 2022SOU EXTENSION 3 GRANTED
Wednesday, October 26, 2022SOU EXTENSION 3 FILED
Friday, November 4, 2022CASE ASSIGNED TO INTENT TO USE PARALEGAL
Wednesday, October 26, 2022SOU TEAS EXTENSION RECEIVED
Saturday, March 26, 2022NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Thursday, March 24, 2022SOU EXTENSION 2 GRANTED
Thursday, March 24, 2022SOU EXTENSION 2 FILED
Thursday, March 24, 2022SOU TEAS EXTENSION RECEIVED
Saturday, August 14, 2021NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Thursday, August 12, 2021SOU EXTENSION 1 GRANTED
Thursday, August 12, 2021SOU EXTENSION 1 FILED
Thursday, August 12, 2021SOU TEAS EXTENSION RECEIVED
Tuesday, April 27, 2021NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Tuesday, March 2, 2021OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, March 2, 2021PUBLISHED FOR OPPOSITION
Wednesday, February 10, 2021NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Monday, January 25, 2021APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, January 20, 2021TEAS/EMAIL CORRESPONDENCE ENTERED
Wednesday, January 20, 2021CORRESPONDENCE RECEIVED IN LAW OFFICE
Tuesday, January 19, 2021ASSIGNED TO LIE
Friday, December 18, 2020APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Friday, December 18, 2020TEAS CHANGE OF CORRESPONDENCE RECEIVED
Friday, December 18, 2020ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Friday, December 18, 2020TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Friday, December 18, 2020TEAS CHANGE OF OWNER ADDRESS RECEIVED
Tuesday, October 6, 2020TEAS RESPONSE TO OFFICE ACTION RECEIVED
Friday, October 2, 2020NOTIFICATION OF EXAMINER'S AMENDMENT/PRIORITY ACTION E-MAILED
Friday, October 2, 2020EXAMINER'S AMENDMENT/PRIORITY ACTION E-MAILED
Friday, October 2, 2020COMBINED EXAMINER'S AMENDMENT/PRIORITY ACTION AUTOMATIC ENTRY
Friday, October 2, 2020EXAMINERS AMENDMENT AND/OR PRIORITY ACTION - COMPLETED
Thursday, September 17, 2020ASSIGNED TO EXAMINER
Friday, August 14, 2020NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Tuesday, July 21, 2020NEW APPLICATION ENTERED

Related Keywords

engex diseases disorders research development services metabolic fibrotic neurological biopharmaceutical pharmaceutical